Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 May 13;30(9):1832–1843. doi: 10.1038/leu.2016.83

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016 Macmillan Publishers Limited

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

Summary of the effects of various inhibitors of IL7R signaling molecules in Ba/F3 cell lines expressing wild-type or mutant IL7Ra, JAK, AKT and RAS. In each plot, the mean ±s.d. IC₅₀ values are shown for each Ba/F3 line (n=3) after doxycycline induction in the absence of IL3. For mutant AKT and N-RAS, two independent lines were tested. The maximum concentrations used were 5 μM for ruxolitinib (a), 125 μM for CI-1040 (b), 16.7 μM for Ly294002 (c) and 5 μM for MK-2206 (d). Cell lines that showed no effect at the maximum inhibitor concentration were considered to be completely resistant to that inhibitor, and thus no IC₅₀ was obtained.